Unexpected worsening of progressive multifocal leucoencephalopathy following COVID-19 pneumonia.
J Neurovirol
; 27(3): 510-513, 2021 06.
Article
in English
| MEDLINE | ID: covidwho-1193171
ABSTRACT
Progressive multifocal leucoencephalopathy is a serious side effect of natalizumab, a humanized monoclonal antibody approved for the treatment of multiple sclerosis. Here, we report a case of unexpected worsening of natalizumab-related progressive multifocal leucoencephalopathy following COVID-19. After natalizumab discontinuation, a slight neurological improvement was observed, but, two months later the patient was admitted to the hospital because of neurological deterioration and COVID-19 mild pneumonia. Except for SARS-CoV-2 infection, no other potential factors of neurological worsening were identified. Thus, we pose the hypothesis that SARS-CoV-2 was instrumental in the progressive multifocal leucoencephalopathy deterioration.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Leukoencephalopathy, Progressive Multifocal
/
Multiple Sclerosis, Relapsing-Remitting
/
Natalizumab
/
COVID-19
Type of study:
Case report
Topics:
Long Covid
Limits:
Humans
/
Male
/
Middle aged
Language:
English
Journal:
J Neurovirol
Journal subject:
Neurology
/
Virology
Year:
2021
Document Type:
Article
Affiliation country:
S13365-021-00980-2
Similar
MEDLINE
...
LILACS
LIS